Position
Engineer IR2 CNRS
Team
Mycobacterial Pathogenesis and Novel Therapeutic Targets
Contact
email : francoise.roquet-baneres(at)irim.cnrs.fr
Phone : +33 (0)4 34 35 94 47
Publications (last 5 years)
2024
Loss of LpqM proteins in Mycobacterium abscessus is associated with impaired intramacrophage survival.
Y.-M. Boudehen, W. Daher, F. Roquet-Baneres, and L. Kremer. 2024. mSpectrum. In Press.
2023
In vitro and in vivo efficacy of NITD-916 against Mycobacterium fortuitum.
F. Roquet-Banères, M. Alcaraz, C. Hamela, J. Abendroth, T. E. Edwards, and L. Kremer. 2023. Antimicrob. Agents Chemother. e01607-22.
2022
Efficacy and Mode of Action of a Direct Inhibitor of Mycobacterium abscessus InhA.
Alcaraz M, Roquet-Banères F, Leon-Icaza SA, Abendroth J, Boudehen YM, Cougoule C, Edwards TE, Kremer L. ACS Infect Dis. 2022 Oct 14;8(10):2171-2186. doi: 10.1021/acsinfecdis.2c00314. Epub 2022 Sep 15. PMID: 3610799
Designing quinoline-isoniazid hybrids as potent anti-tubercular agents inhibiting mycolic acid biosynthesis.
Alcaraz, B. Sharma, F. Roquet-Banères, C. Conde, T. Cochard, F. Biet, V. Kumar, and L. Kremer. 2022. Eur. J. Med. Chem. 239: 114531.
2021
Mycobacterium abscessus, un modèle de résistance aux différentes classes d’antibiotiques.
M. Illouz, M. Alcaraz, F. Roquet-Banères, and L. Kremer. 2021. Med. Sci. 37: 993-1001.
Mycobacteriophage-antibiotic therapy promotes enhanced clearance of drug-resistant Mycobacterium abscessus
D. Johansen, M. Alcaraz, R.M. Dedrick, F. Roquet-Banères, C. Hamela, G. F. Hatfull, and L. Kremer. 2021. Dis. Model. Mech. 14: dmm049159.
2020
Design and synthesis of 4-Aminoquinoline-isoindoline-dione-isoniazid triads as potential anti-mycobacterials.
Rani A, Johansen MD, Roquet-Banères F, Kremer L, Awolade P, Ebenezer O, Singh P, Sumanjit, Kumar V. Bioorg Med Chem Lett. 2020 Sep 24;30(22):127576. doi: 10.1016/j.bmcl.2020.127576.
Rifabutin is bactericidal against intracellular and extracellular forms of Mycobacterium abscessus.
Johansen MD, Daher W, Roquet-Banères F, Raynaud C, Alcaraz M, Maurer FP, Kremer L.Antimicrob Agents Chemother. 2020 Aug 17:AAC.00363-20. doi: 10.1128/AAC.00363-20.
Synergistic interactions of indole-2-carboxamides and β-lactam antibiotics against Mycobacterium abscessus.
Raynaud C, Daher W, Roquet-Banères F, Johansen MD, Stec J, Onajole OK, Ordway D, Kozikowski AP, Kremer L.
Antimicrob Agents Chemother 2020 Feb 10. pii: AAC.02548-19. doi: 10.1128/AAC.02548-19.
Active Benzimidazole Derivatives Targeting the MmpL3 Transporter in Mycobacterium abscessus.
Raynaud C, Daher W, Johansen MD, Roquet-Banères F, Blaise M, Onajole OK, Kozikowski AP, Herrmann JL, Dziadek J, Gobis K, Kremer L.
ACS infectious diseases ACS Infect Dis 2020 Jan 7. doi: 10.1021/acsinfecdis.9b00389.
2019
A piperidinol-containing molecule is active against Mycobacterium tuberculosis by inhibiting the mycolic acid flippase activity of MmpL3.<
Dupont C, Chen Y, Xu Z, Roquet-Banères F, Blaise M, Witt AK, Dubar F, Biot C, Guérardel Y, Maurer FP, Chng SS, Kremer L.
The Journal of biological chemistry>J Biol Chem. 2019 Nov 15;294(46):17512-17523. doi: 10.1074/jbc.RA119.010135.
The TetR-family transcription factor MAB_2299c regulates the expression of two distinct MmpS-MmpL efflux pumps involved in cross-resistance to clofazimine and bedaquiline in Mycobacterium abscessus.
Gutiérrez AV, Richard M, Roquet-Banères F, Viljoen A, Kremer L.
Antimicrobial agents and chemotherapy 2019 Jul 22. pii: AAC.01000-19. doi: 10.1128/AAC.01000-19.
Improved activity of bedaquiline by verapamil against Mycobacterium abscessus in vitro and in macrophages.
Viljoen A, Raynaud C, Johansen MD, Roquet-Banères F, Herrmann JL, Daher W, Kremer L.
Antimicrobial agents and chemotherapy. 2019 Jun 17. pii: AAC.00705-19. doi: 10.1128/AAC.00705-19.
